EUVIMEDSkopri EUVIMED
Open access

AUS in Thyroid Cytology: A 21‐Year Institutional Experience and the Impact of Atypia Subclassification

Olcay Kurtulan iD, Irem Kilic iD, Swati Mehrotra iD, Eva M Wojcik iD, Güliz A Barkan iD

Diagnostic Cytopathology · 2026-09 · 54 (9) · 653-662

DOI: 10.1002/dc.70149 ↗

At a glance

Journal article in Diagnostic Cytopathology, published online on 2026-06-02. Written by Olcay Kurtulan and 4 co-authors. Institution: Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey. Major MEDLINE topics: Thyroid Neoplasms, Thyroid Gland, Thyroid Nodule. 45 references. The full text is freely available in PubMed Central.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

The Atypia of Undetermined Significance (AUS) category remains one of the most controversial groups in The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). We aimed to assess AUS outcomes at our institution over a 21‐year period.

Methods

Thyroid fine needle aspiration (FNA) cases between 2000 and 2021 were retrospectively reviewed, and AUS diagnoses were identified. Cases were subclassified as nuclear (AUS‐N) or other atypia (AUS‐O). The AUS rates per year and cytopathologist, risk of malignancy (ROM), and radiological features were analyzed.

Results

There were 15,099 thyroid FNAs, of which 553 initial AUS cases were included. The AUS rate was 0.7% and 6.6% before and after the implementation of the TBSRTC. AUS rates among cytopathologists ranged from 2.8% to 8.8%. Of the 553 cases, 168 (30%) underwent surgery, 269 (48.6%) had a repeat FNA, and 116 (20.9%) were observed or lost to follow‐up. Pre‐TBSRTC the overall ROM was 20%, and post‐TBSRTC 30.1% and 26.7% when NIFTP was considered malignant, and nonmalignant, respectively. ROM was significantly higher in AUS‐N than AUS‐O (39% vs. 20.7% with NIFTP malignant; 36% vs. 17.6% without; p < 0.01). ROM did not differ significantly between patients with one or two consecutive AUS diagnoses (26.7% vs. 25%). On ultrasonographic findings, calcifications, and cystic changes were more frequent in AUS‐N, while nodule size and multiplicity were similar between groups.

Conclusion

In conclusion, AUS‐N and AUS‐O demonstrated significantly different ROMs, supporting the 2023 TBSRTC subclassification. Repeat FNA led to diagnostic reclassification in a substantial proportion of cases, supporting its role as an acceptable management strategy, particularly in settings with limited access to molecular testing.

Subjects

MeSH terms (MEDLINE)

Thyroid NeoplasmsThyroid GlandThyroid NoduleHumansBiopsy, Fine-NeedleRetrospective StudiesFemaleMaleMiddle AgedAdultAged

Author keywords

AUS‐nuclearAUS‐otherFNAatypia of undetermined significancerisk of malignancy—ROMthyroid

Authors and institutions

  • Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Department of Pathology and Laboratory Medicine, Loyola University Health System, Maywood, Illinois, USA.

ORCID profiles: Olcay Kurtulan, Irem Kilic, Swati Mehrotra, Eva M Wojcik, Güliz A Barkan

Cite

APA

Kurtulan, O., Kilic, I., Mehrotra, S., Wojcik, E. M., & Barkan, G. A. (2026). AUS in Thyroid Cytology: A 21‐Year Institutional Experience and the Impact of Atypia Subclassification. Diagnostic Cytopathology, 54(9), 653-662. https://doi.org/10.1002/dc.70149

Vancouver

Kurtulan O, Kilic I, Mehrotra S, Wojcik EM, Barkan GA. AUS in Thyroid Cytology: A 21‐Year Institutional Experience and the Impact of Atypia Subclassification. Diagnostic Cytopathology. 2026;54(9):653-662. doi:10.1002/dc.70149

BibTeX
@article{Kurtulan2026,
  author = {Kurtulan, Olcay and Kilic, Irem and Mehrotra, Swati and Wojcik, Eva M and Barkan, Güliz A},
  title = {AUS in Thyroid Cytology: A 21‐Year Institutional Experience and the Impact of Atypia Subclassification},
  journal = {Diagnostic Cytopathology},
  year = {2026},
  volume = {54},
  number = {9},
  pages = {653--662},
  doi = {10.1002/dc.70149}
}
Start for free →